No Debt, $87.5M in Cash, and a 29% Net Margin. The Revenue Line Is the Only Question.

A specialty medical device maker focused on women's and infant health that earned a 29.3% net margin on $38.5M of FY2025 revenue, carries no debt, and held $87.5M in cash and investments at June 30, 2026. Revenue is shrinking after the loss of its two largest customers, and the company has told shareholders to expect a 10% to 13% decline in 2026. The balance sheet is settled; the revenue line is the open question.

Analysis

Utah Medical Products designs, manufactures, and sells disposable and reusable specialty medical devices, with a particular focus on health care for women and their babies, and clinicians in more than one hundred countries use its products. The company is small by any measure. FY2025 revenue was $38.5M, down 5.8% from the prior year, and quarterly net sales have drifted from $11.34M in the first quarter of 2024 to $8.53M in the second quarter of 2026. What makes it unusual is what it keeps. FY2025 net income was $11.3M, a net margin of 29.3%, and gross margin held at 57.1% while revenue fell. Income before tax was 36.6% of sales. Very few companies of any size convert more than a third of their revenue into pretax profit, and this one did it in a down year.

The balance sheet is the strategic fact. At June 30, 2026, the company held $87.5M in cash and investments with no debt, up from $85.8M at the end of 2025, after paying $2.0M in dividends and repurchasing $0.2M of stock during the first half. Working capital stood at $98.6M with a current ratio of 48.6. In a market where the ten-year Treasury yield has crossed 5%, that cash is no longer idle: it earns a real return on its own, and the company will never need to ask the capital markets for a dollar on the market's terms. For a micro-cap, the absence of any financing need is itself a moat, and it is the reason the desk initiates coverage in a week when financing costs are the story.

The Human Translation: this is a very profitable small company that lost its two biggest customers and has not yet replaced them. The products that remain still earn fat margins, the company has almost ninety million dollars in the bank and owes nothing, and it pays a dividend and buys back its own shares. The question is not whether the company survives. It is whether the revenue decline stops, and when.

The revenue problem is specific, and the company has named it. The decline traces overwhelmingly to the loss of sales to its two previously largest customers. In the second quarter of 2026, lost sales to those two accounts were $1.07M, or 75% of the year-over-year decline; for the first half, $1.92M, or 80%. One of them was PendoTECH, a biopharma customer whose purchases had already been falling through 2025, and the company also recorded a write-off on a cancelled distribution business in China. Combined 2025 sales to the two customers were $2.89M, which management planned to recover in 2026 through new products sold to other biopharma OEM customers. First-half 2026 sales to those new customers were $211K, and the company called that progress slower than expected.

Management's own guidance frames the year. Full-year 2026 revenue is now projected to decline 10% to 13% against 2025 as new product sales ramp more slowly than planned, and litigation expense will exceed the 2025 level even with an expected decline in the second half. The desk reads this as a company telling shareholders the uncomfortable number in advance, which is consistent with how it has reported for years. Its releases are dense, precise, and occasionally blunt; the FY2025 release opened by stating plainly that the company did not achieve its beginning-of-year projections. A management team that leads with the miss is easier to underwrite than one that buries it.

Margins are where the quality shows. Second-quarter 2026 gross margin was 55.8% against 56.2% a year earlier, pressured by tariffs and lower volume, but first-half gross margin improved to 58.2% from 56.6% on a more favorable mix. Operating margin was 31.1% in the second quarter. Adjusted EBITDA for the first half was $7.57M, or 43.9% of sales, down from $9.32M a year earlier. A company that loses 12% of its revenue and still earns a 44% EBITDA margin is running product lines with genuine pricing power, not commodities. The fixed cost base is what turns the revenue decline into a larger profit decline, and it is also what would turn a recovery into a larger profit recovery.

Capital return has been the steady counterweight to the revenue line. In 2025 the company returned $12.3M to shareholders through dividends and buybacks, 109% of net income, including $4.0M in dividends and $8.4M to repurchase 4.5% of its shares in the open market. In 2024 it returned $24.2M, 175% of net income. Shrinking the share count with surplus cash is how per-share results have held up better than totals: 2025 net income fell 19% while earnings per share fell 12%. Dividends totaled $1.22 per share in 2025, paid at 30.5 cents a quarter, and the cash balance still rose.

The product franchise is concentrated in obstetrics, gynecology, and neonatal care, where device choices tend to be sticky. Clinicians who train on a device tend to keep using it, and hospital purchasing committees rarely switch a specialty product that works to save a small amount on unit cost. The company also sells its Filshie clip system internationally, and weakness in those sales outside the United States contributed to the 2025 decline alongside the lost customers. The company reports results in U.S. dollars alongside euros, British pounds, Australian dollars, and Canadian dollars, which adds currency translation swings to reported figures in both directions.

The unusual items are small but deserve naming, because the desk names everything. FY2025 general and administrative expense included a $395K write-off tied to the cancelled China distribution business, a $195K loss from embezzlement by the former manager of the Australian subsidiary, and currency effects from a stronger euro and pound. None of these changes the thesis. Together they are a reminder that a company this size feels individual events directly in its reported margins, and the second-quarter release flagged higher litigation expense as a drag on 2026 results.

Regulation is a barrier that protects incumbents in this category. Medical devices sold into hospitals require clearance and ongoing quality-system compliance, and switching suppliers means revalidating products in clinical settings. That friction limits how quickly a competitor can take share from an established specialty product, and it helps explain how gross margin held near 57% through a year of falling revenue. The same friction slows the company's own efforts to win new OEM customers, which is part of why the biopharma ramp has run behind plan.

Management's record is one of discipline over expansion. The company has not spent its cash on a large acquisition to buy revenue back, and it has not diluted shareholders to fund growth; no employee options were awarded in 2026 through the first half. That restraint is the reason the balance sheet looks the way it does. It also means the revenue problem will be solved by product and customer work rather than by a transaction, which is slower and, if it works, more durable.

On valuation, the desk holds to its discipline of no price targets. What the record does support is an observation about composition: the shares ended 2025 at $55.96, down 9% in a year when the Dow, the S&P 500, and the Nasdaq all rose, while cash and investments kept climbing. A shrinking revenue line has been priced in; a growing cash balance has been largely ignored. Whether that gap closes depends on the variable the company does not fully control, which is how quickly new biopharma customers replace the ones it lost.

The rate backdrop cuts in the company's favor in a way that is easy to miss. The weekly roundup has tracked the ten-year Treasury yield through 5% and a Federal Reserve that raised rates in September for the first time since 2023. For companies that fund growth with equity or debt, that is a headwind. For a company holding $87.5M in cash and investments with nothing borrowed, higher rates raise the return on the balance sheet itself. In this regime the ledger sorts by who needs capital and who has it, and this company sits firmly on the second side.

The operating leverage cuts both ways, and the 2025 numbers show it precisely. Revenue fell 6%, gross profit fell 9%, operating income fell 16%, and net income fell 19%. Each step down the income statement amplified the decline, because a manufacturer carries plant, quality, and regulatory costs that do not shrink with volume. The same arithmetic runs forward: if new OEM products bring back even part of the $2.89M in lost annual sales, most of each recovered dollar falls through to profit, because the infrastructure to make it is already paid for. That asymmetry is the operating case sitting inside the balance sheet case.

The quarterly series gives the clearest view of where the decline stands. Net sales were $11.34M in the first quarter of 2024, then $10.40M, $10.01M, and $9.17M through the rest of that year. In 2025 they held in a narrow band of $9.71M, $9.95M, $9.81M, and $9.04M, before stepping down to $8.72M and $8.53M in the first two quarters of 2026. The 2025 plateau showed the core business holding once the first customer loss was absorbed; the 2026 step reflects the second. In the first half of 2026, net income fell 13.1% on a 12.3% revenue decline, nearly in line, as a better gross margin offset most of the lost volume and the higher litigation cost. The next several quarters will show whether a new floor forms near $8.5M a quarter.

The scenario map has three branches. In the first, new biopharma OEM sales ramp through 2027, the revenue decline flattens, and the margin structure carries the business back to growth from a smaller base, with capital returns continuing throughout. In the second, the decline continues at a slower pace, the company keeps earning high margins on a shrinking line, and the cash balance keeps climbing, which is a slow return of capital rather than a growth story. In the third, the losses spread beyond the two named customers into the core women's health franchise, and the thesis would need to be rebuilt. The desk does not weight the branches; it names them so each filing can be read against the map.

The checkpoint set, stated fully. First, quarterly net sales against the prior-year quarter, which shows whether the decline narrows as the company laps the lost customers. Second, sales to new biopharma OEM customers, $211K in the first half of 2026 and the single number that decides whether the lost revenue is recoverable. Third, gross margin, the pricing-power readout, which held at 58.2% for the first half. Fourth, the cash balance and capital returns, which show whether the balance sheet keeps compounding. The thesis weakens if new customer sales stay negligible through 2027 while core sales erode; it strengthens the first quarter revenue grows year over year again.

The Human Translation

Utah Medical makes specialized medical devices, mostly for women's health and newborns, and it is extremely profitable for its size: about 29 cents of every sales dollar became profit in 2025. It has no debt and about $87.5M in cash and investments. The problem is that sales have been shrinking since it lost its two biggest customers, and the company expects 2026 revenue to fall another 10% to 13%. The bet is on a fortress balance sheet waiting for its revenue line to stop falling.

Bottom Line

Watch sales to new biopharma OEM customers, $211K in the first half of 2026, and quarterly net sales against the prior year. The first says whether the lost revenue is recoverable; the second says whether the decline is narrowing. The cash balance, $87.5M at June 30, is the floor under both.

Quick Facts

More from the research desk: ACON, COSM, MDAI, and the full library